Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes
- PMID: 38836748
- DOI: 10.1089/met.2024.0022
Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes
Abstract
Objective: Nonalcoholic fatty liver disease (NAFLD) is more prevalent in patients with obesity, diabetes, and metabolic syndrome, which are risk factors for nonalcoholic steatohepatitis and liver fibrosis. NAFLD is related to cardiovascular outcomes in diabetes. We aimed to investigate the relationship between diabetic complications and NAFLD fibrosis score (NFS) and Fibrosis-4 score (FIB-4). Methods: Three hundred patients with type 2 diabetes mellitus (T2DM) were retrospectively evaluated according to NAFLD diagnosis on ultrasound in outpatient clinic. Risk of advanced fibrosis was estimated using FIB-4 and NFS. Diabetic complications of the patients were noted. Results: Presence of diabetic retinopathy is related to FIB-4 (P = 0.001) and NFS (P < 0.001) scores. NFS score (P = 0.037), not FIB-4 (P = 0.517), is related to diabetic nephropathy. Among macrovascular complications, only coronary artery disease is related to NFS and FIB-4 scores (P = 0.037 and P = 0.004, respectively). Although we cannot establish any association between fasting blood glucose, glycosylated hemoglobin (HbA1c) values and noninvasive liver fibrosis scores (P > 0.05), diabetes duration, and age positively correlated with the FIB-4 score (P = 0.033, P = 0.001). In logistic regression analysis, NFS > 0.676 values are associated with increased rates of diabetic retinopathy, independent of age, sex, HbA1c, and duration diabetes (odds ratio: 1.155, P = 0.030). FIB-4 has no relation with microvascular complications according to logistic regression analysis (P > 0.05 for all). Neither FIB-4 nor NFS has an effect on the presence of macrovascular complications (P > 0.05 for all). Conclusion: Our findings suggest that increase in NFS score is associated with the presence of diabetic retinopathy, independent of confounding factors. Further studies are needed on the applicability of noninvasive fibrosis scores in monitoring the presence of diabetic microvascular and macrovascular complications.
Keywords: NAFLD; diabetes complications; diabetes mellitus; fibrosis.
Similar articles
-
Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus.Arab J Gastroenterol. 2024 Aug;25(3):269-274. doi: 10.1016/j.ajg.2024.04.001. Epub 2024 May 7. Arab J Gastroenterol. 2024. PMID: 38719663
-
Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3661-e3669. doi: 10.1210/clinem/dgac382. J Clin Endocrinol Metab. 2022. PMID: 35766414
-
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.BMJ Open Diabetes Res Care. 2020 Feb;8(1):e000904. doi: 10.1136/bmjdrc-2019-000904. BMJ Open Diabetes Res Care. 2020. PMID: 32049637 Free PMC article.
-
Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis.Eur J Clin Invest. 2022 Nov;52(11):e13855. doi: 10.1111/eci.13855. Epub 2022 Sep 7. Eur J Clin Invest. 2022. PMID: 36001034
-
The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2022 Dec 1;34(12):1277-1284. doi: 10.1097/MEG.0000000000002462. Epub 2022 Oct 17. Eur J Gastroenterol Hepatol. 2022. PMID: 36317774
Cited by
-
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas). 2024 Dec 30;61(1):38. doi: 10.3390/medicina61010038. Medicina (Kaunas). 2024. PMID: 39859020 Free PMC article. Review.
-
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.Nat Rev Gastroenterol Hepatol. 2025 May;22(5):314-328. doi: 10.1038/s41575-025-01045-z. Epub 2025 Feb 17. Nat Rev Gastroenterol Hepatol. 2025. PMID: 39962331 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical